Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260698 · ClinicalTrials.gov registry record · Phase 3
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
A Phase 3 study of Hematological Malignancies, sponsored by Gamida Cell.
- Completed
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
- 6
- Study locations
NCT04260698 is a Phase 3 study of Hematological Malignancies that has completed, run by Gamida Cell. The registered enrollment target is 36 participants, below the 774-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04260698, a Phase 3 study of Hematological Malignancies, has completed, sponsored by Gamida Cell.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
- 6
- Study locations
Study Summary
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
Conditions Studied
Interventions
- BIOLOGICAL omidubicel
Study Locations (6)
California
- UCLA - Los Angeles
- Stanford University Cancer Institute - Palo Alto
Illinois
- Loyola University, Cardinal Bernardin Cancer Center - Maywood
Minnesota
- University of Minnesota Masonic Cancer Center - Minneapolis
North Carolina
- Duke University Medical Center - Durham
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04260698
The ClinicalTrials.gov registry entry for NCT04260698 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 774-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (95% lower). The listed sponsor is Gamida Cell, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which omidubicel is the first listed.
NCT04260698 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04260698 about?
NCT04260698 is a clinical study titled "Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies". Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
What is the current status of trial NCT04260698?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2020-07-08. Estimated completion is 2025-05-08.
What conditions does trial NCT04260698 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT04260698?
The interventions under investigation include: omidubicel (BIOLOGICAL).
Who is sponsoring clinical trial NCT04260698?
This trial is sponsored by Gamida Cell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04260698 being conducted?
This trial has 6 study locations across California, Illinois, Minnesota, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
-
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.